Quick Answer
Spyre Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Spyre Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 -100.0% |
$886.0K -62.0% |
$2.33M -87.6% |
$18.74M | $0.00 |
| Revenue (ASC 606) | $0.00 | $0.00 -100.0% |
$886.0K -62.0% |
$2.33M -87.6% |
$18.74M | $0.00 |
| Net Income | -$155.20M +25.4% |
-$208.02M +38.6% |
-$338.79M -304.2% |
-$83.81M -27.4% |
-$65.80M +18.7% |
-$80.89M -3.4% |
| Diluted EPS | — | — | -$49.12 -97.6% |
-$24.86 +0.6% |
-$25.02 -1546.1% |
-$1.52 |
| Total Assets | $777.78M +27.8% |
$608.48M +78.0% |
$341.86M +380.5% |
$71.14M -35.3% |
$109.93M -32.0% |
$161.62M +94.3% |
| Cash and Equivalents | $85.72M -4.1% |
$89.42M -52.7% |
$188.89M +441.8% |
$34.86M +130.2% |
$15.14M -83.2% |
$90.09M +368.0% |
| Stockholders Equity | $715.24M +38.1% |
$517.80M +181.4% |
$184.02M +265.8% |
$50.30M -40.1% |
$83.94M -40.0% |
$139.83M +132.7% |
| R&D Expense | — | — | — | $58.58M +2.6% |
$57.07M -4.3% |
$59.64M -7.7% |
| Operating Income | -$209.56M -0.5% |
-$208.57M +13.9% |
-$242.30M -185.8% |
-$84.78M -29.1% |
-$65.65M +19.4% |
-$81.48M -1.4% |
| Shares Outstanding | 78.19M +29.8% |
60.26M +67.1% |
36.06M +1279.4% |
2.61M -94.7% |
49.36M +2.9% |
47.96M +64.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$11.18M | +83.8% | +69.5% |
| Diluted EPS | September 30, 2024 | -$1.36 | +85.4% | -58.1% |
| Total Assets | September 30, 2025 | $504.60M | +19.8% | -6.4% |
| Cash and Equivalents | September 30, 2025 | $64.90M | -9.3% | -20.5% |
| Stockholders Equity | September 30, 2025 | $455.10M | +39.0% | -0.1% |
| R&D Expense | March 31, 2023 | $13.78M | -18.9% | +15.0% |
| Operating Income | September 30, 2025 | -$56.89M | -2.7% | -35.7% |
| Shares Outstanding | September 30, 2025 | 60.47M | +17.7% | +0.2% |
- Spyre Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Spyre Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Spyre Therapeutics, Inc. reported Net Income of -$155.20 million for fiscal year 2025.
- Spyre Therapeutics, Inc. showed an increase of +25.4% in Net Income compared to the prior fiscal year.
- Spyre Therapeutics, Inc. reported Diluted EPS of $49.12 per share (loss) for fiscal year 2023.
- Spyre Therapeutics, Inc. showed a decrease of -97.6% in Diluted EPS compared to the prior fiscal year.
- Spyre Therapeutics, Inc. reported Total Assets of $777.78 million for fiscal year 2025.
- Spyre Therapeutics, Inc. showed an increase of +27.8% in Total Assets compared to the prior fiscal year.
- Spyre Therapeutics, Inc. reported Cash and Equivalents of $85.72 million for fiscal year 2025.
- Spyre Therapeutics, Inc. showed a decrease of -4.1% in Cash and Equivalents compared to the prior fiscal year.
- Spyre Therapeutics, Inc. reported Stockholders Equity of $715.24 million for fiscal year 2025.
- Spyre Therapeutics, Inc. showed an increase of +38.1% in Stockholders Equity compared to the prior fiscal year.
- Spyre Therapeutics, Inc. reported R&D Expense of $58.58 million for fiscal year 2022.
- Spyre Therapeutics, Inc. showed an increase of +2.6% in R&D Expense compared to the prior fiscal year.
- Spyre Therapeutics, Inc. reported Operating Income of -$209.56 million for fiscal year 2025.
- Spyre Therapeutics, Inc. showed a decrease of -0.5% in Operating Income compared to the prior fiscal year.
- Spyre Therapeutics, Inc. reported Shares Outstanding of 78.19 million shares for fiscal year 2025.
- Spyre Therapeutics, Inc. showed an increase of +29.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: